By Fineline Cube 
China‑based NeuroGen Pharma and Bocimed announced today that they have entered into an exclusive product‑transfer agreement for Brexpiprazole Orally Disintegrating Film (ODF). Under the deal, Bocimed will transfer the mainland China marketing authorization, core patents, and proprietary technology to NeuroGen Pharma, granting it exclusive rights for research & development, registration, manufacturing, and commercialization across the Greater China region (Hong Kong, Macau, and Taiwan).
Deal Highlights
| Item | Detail |
|---|---|
| Parties | NeuroGen Pharma (China) & Bocimed (China) |
| Product | Brexpiprazole Orally Disintegrating Film (ODF) |
| Rights Granted | R&D, registration, manufacturing, and commercialization (all indications) in Greater China |
| Underlying IP | Mainland China marketing authorization, core patents, proprietary fast‑dissolving film technology |
| Strategic Rationale | Leverages NeuroGen’s manufacturing footprint and Bocimed’s ODF breakthrough to improve medication adherence in schizophrenia patients |
About Brexpiprazole ODF
- Origin: Developed by Otsuka Pharmaceutical as a next‑generation atypical antipsychotic.
- Clinical Profile: Provides antipsychotic efficacy with reduced extrapyramidal symptoms and sedation; improves negative symptoms and cognitive function.
- Regulatory Status: FDA‑approved (schizophrenia, adjunctive depression, 2023 Alzheimer’s agitation); NMPA‑approved in June 2024.
- Formulation Advantage: Bocimed’s Class 2.2 ODF utilizes oral fast‑dissolving film technology that dissolves on the palate without water, enhancing adherence, lowering nursing costs, and reducing relapse risk.
- Commercial Milestone: Marketing application filed September 2024; approval pending by NMPA.
Strategic Impact
- For NeuroGen Pharma – The exclusive license positions the company as a leading antipsychotic supplier in Greater China, expanding its portfolio and reinforcing its commitment to patient‑centric formulations.
- For Bocimed – The transfer enables Bocimed to monetize its proprietary ODF platform while focusing on future drug‑delivery innovations.
- For Patients – The ODF format addresses longstanding adherence challenges in schizophrenia, potentially improving therapeutic outcomes and reducing healthcare burden.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech